A Review on Repositioning Antidiabetic Therapies for Alzheimer’s and Parkinson’s Disease: Targeting the Metabolic–Neurodegenerative Interface

Key Points

• Findings suggest that antidiabetic therapies may benefit neurodegenerative disorders, enhancing overall treatment approaches.
• The review discusses potential mechanisms linking metabolism and neurodegeneration, with implications for therapeutic strategies.
• Assessment involves exploring existing therapies and their effects on both Alzheimer’s and Parkinson’s symptoms through the metabolic interface.
• The repositioning of these therapies could significantly reshape treatment landscapes in neurodegenerative diseases.